SCHEMBL88337

SCHEMBL88337

Oc1cccc2c1CCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.42
ICAM1 P05362 1/20 0.42
ITGAL P20701 1/20 0.42
BCL2L1 Q07817 1/20 0.42
BAD Q92934 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
SLC9A1 P19634 2/20 0.40
PTGS2 P35354 1/20 0.40
MTNR1B P49286 6/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC9A5 Q14940 1/20 0.38
SLC9A2 Q9UBY0 1/20 0.38
LMNA P02545 2/20 0.38
CRHBP P24387 2/20 0.38
CRHR2 Q13324 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
AKT1 P31749 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30054966 1.00 ITGB2 (0.42) ITGB2ICAM1ITGALBCL2L1BAD
Formaldehyde SCHEMBL10956682 0.94 MAOA (0.41) ITGB2ICAM1ITGALBCL2L1BAD
SCHEMBL5673196 0.88 BCL2L1 (0.48) ITGB2ICAM1ITGALBCL2L1BAD
SCHEMBL31598947 0.88 BCL2L1 (0.48) ITGB2ICAM1ITGALBCL2L1BAD
SCHEMBL3131795 0.79 BCL2L1 (0.39) BCL2L1BADMAOAMAOBPTGS2
SCHEMBL2938129 0.76 MAOA (0.38) MAOAMAOBSLC9A1MTNR1BMEN1
SCHEMBL19667519 0.75 PNMT (0.41) ITGB2ICAM1ITGALBCL2L1BAD
SCHEMBL945134 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALSLC9A1MTNR1B
SCHEMBL2830923 0.74 ITGB2 (0.42) ITGB2ICAM1ITGALSLC9A1MTNR1B
SCHEMBL8081108 0.74 MAP3K14 (0.47) ITGB2ICAM1ITGALMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4347571-B1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. HOFFMANN LA ROCHE (CH) 2026-04-22 EP claimed
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE SCRIPPS RESEARCH INST (US) 2026-04-02 US claimed
EP-4642784-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2025-11-05 EP claimed
EP-4630420-A1 INHIBITORS OF NLRP3 F. Hoffmann-La Roche AG (CH) 2025-10-15 EP claimed
EP-4584236-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE The Scripps Research Institute (US) 2025-07-16 EP claimed
WO-2024145623-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2024-07-04 WO claimed
WO-2024121184-A1 INHIBITORS OF NLRP3 F. HOFFMANN-LA ROCHE AG (CH) 2024-06-13 WO claimed
WO-2024054881-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE THE SCRIPPS RESEARCH INSTITUTE (US) 2024-03-14 WO claimed
EP-1323410-B1 Sunscreen emulsion composition and method of use AVON PROD INC (US) 2006-09-13 EP claimed
EP-1323410-A2 Sunscreen emulsion composition and method of use AVON PRODUCTS, INC. (US) 2003-07-02 EP claimed
US-6517816-B1 Inner discontinuous phase and an outer continuous phase AVON PRODUCTS, INC. 2003-02-11 US claimed
EP-0252835-B1 PROCESS FOR QUICK ELIMINATION OF HYDROGEN SULPHIDE CONTAINED IN LIQUID SULPHUR, AND CATALYTIC SYSTEM TO CARRY IT OUT SOCIETE NATIONALE ELF AQUITAINE (PRODUCTION) (FR) 1990-11-07 EP claimed
US-20260125381-A1 NOVEL Kv3 CHANNEL MODULATORS MERCK SHARP & DOHME LLC (US) 2026-05-07 US disclosed
EP-4347571-B1 TRIAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER. HOFFMANN LA ROCHE (CH) 2026-04-22 EP disclosed
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE SCRIPPS RESEARCH INST (US) 2026-04-02 US disclosed
WO-2026046981-A1 SOLID FORMS OF 5-[3-[[(3R)-1-ETHYL-3-PIPERIDYL]AMINO]-5-METHYL-1,2,4-TRIAZIN-6-YL]-2,3- DIHYDROBENZOFURAN-4-OL F. HOFFMANN-LA ROCHE AG (CH) 2026-03-05 WO disclosed
US-4494979-A HERBICIDES;PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-01-22 US disclosed
US-4488896-A Methods and compositions for the selective control of undesirable weed species in the presence of wet-land crops AMERICAN CYANAMID COMPANY (US) 1984-12-18 US disclosed
EP-0071441-A2 Benzofuran sulfamates E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-02-09 EP disclosed
US-4289640-A IMPROVED FOAMING AND DEGREASING PROPERTIES COLGATE-PALMOLIVE COMPANY (US) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092029-A1 LIGAND-ENABLED SCALABLE C-H HYDROXYLATION OF BENZOIC AND PHENYLACETIC ACIDS AT ROOM TEMPERATURE CYP2B6, CYP2A6, CYP1A1 ITGB2 3203/4885ICAM1 2138/4885ITGAL 3047/4885
US-20260125381-A1 NOVEL Kv3 CHANNEL MODULATORS KCNN3, KCNA3, KCNQ3 ITGB2 2343/4885ICAM1 1527/4885ITGAL 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.